Investors Are Bullish On The Stocks $D $NTES $REGN Based On Bollinger Band – Wire Real Estate

Investors Are Bullish On The Stocks $D $NTES $REGN Based On Bollinger Band




Aug 7, 2020

Wire.RealEstate powered by Google



*If You Own D, NTES, REGN Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NYSE:D), (NASDAQ:NTES) or (NASDAQ:REGN), and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/ Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Dominion Energy acquired by Berkshire Hathaway

https://themarketsignal.com/Free-Report/D

(Click link above or copy, paste and hit enter in your browser for your report)

Dominion Energy Inc (NYSE:D) shows bullish potential as its stock price trades $73.41 above its 20 Days Bollinger Band.

The bullish momentum highlights investor excitement following the company's acquisition by Berkshire Hathaway. The latter is known for investing in stocks that have a lot of growth potential during Warren Buffett's tenure as CEO, during which Berkshire Hathaway has managed to build a strong portfolio of acquisitions.

Berkshire Hathaway acquired Dominion Energy for $10 billion. This includes $4 billion for the company and $6 billion for the company's debt. This is also a significant purchase for the stock market because it is the first major purchase for Buffett's company ever since the coronavirus pandemic sent the market into a downward spiral in March.

The purchase will become part of Berkshire Hathaway Energy which will control roughly

18% of natural gas distribution across the interstate natural gas network in the U.S. The company currently controls 8% and so the purchase of Dominion Energy will contribute the additional 10%.

NetEase to offer its cloud music service to 88VIP subscribers

https://themarketsignal.com/Free-Report/NTES

(Click link above or copy, paste and hit enter in your browser for your report)

NetEase Inc (NASDAQ:NTES) stock price has a bullish outlook as it traded above the 20 Days Bollinger Band $440.78 by the end of the last trading session.

Netease Cloud Music revealed that it plans to provide its music streaming service as a perk to subscribers of Alibaba's customer loyalty plan called 88VIP. Netease Cloud Music is a subscription-based service that costs RMB 179 ($26) annually.

The music streaming platform will be accessible to 88VIP members as soon as August 7 and they will not have to pay an extra charge for the service. However, non 88VIP members who have a Taori value (a score calculated from a user's purchase history and individual credit) above 1,000 can become 88VIP members by paying a discounted fee of RMB 88. In comparison, those that do not have a Taori value above 1,000 would have to pay RMB 888 to become 88VIP members.

The company expects the difference in the membership pricing will encourage more user engagement on the platform so that they can earn enough loyalty scores to achieve the discounted prices.

Regeneron Pharmaceuticals observes significant anti-COVID-19 findings in preclinical trials of its antibody-drug combination

https://themarketsignal.com/Free-Report/REGN

(Click link above or copy, paste and hit enter in your browser for your report)

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) demonstrates bullish potential as it traded above its 20 Days Bollinger Band $610.71 in the last trading session.

Regeneron revealed that its antibody drug combo for treating COVID-19 demonstrated the ability to treat and prevent COVID-19 in hamsters and macaques. The results were observed in the company's preclinical trial and this means that there is a likelihood that the results might be similar in human subjects.

The biopharma stated that the drug combination which contains two monoclonal antibodies managed to almost completely block COVID-19 from infecting the subjects. It did however state that the animal study was not peer-reviewed.

The company's report on the animal trial indicated that the drug combo managed to subdue the infection in a study where the animal subjects were infected with a high viral load. Regeneron also revealed that it observed a significantly reduced prophylactic effect in animal subjects that were treated with a lower dose of the drug combination. the company also stated that the results of the animal study managed to outperform recent animal studies involving other COVID-19 vaccine candidates.

The findings from the preclinical study also revealed that animals that were treated with the antibody combo regained their health faster than the animals in the placebo arm. Regeneron also revealed that it has commenced its late-stage human clinical trials to determine the drug combo's efficacy.

Regeneron is also in a strong position to bring the treatment combo to market if the clinical trials provide favorable results. This is because the biopharma recently secured a $450 million contract under the U.S government's program called Operation Warp Speed. The latter means that the drug will be rapidly distributed across the U.S if it proves successful.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_369032380/2703/2020-08-07T09:59:01

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.